Have a personal or library account? Click to login
Development of two different eco-friendly label-free platforms for analysis of selumetinib Cover

Development of two different eco-friendly label-free platforms for analysis of selumetinib

Acta Pharmaceutica
Volume 75 (2025): Issue 3 (September 2025)
By:
Open Access
|Oct 2025

References

  1. D. H. Gutmann, R. E. Ferner, R. H. Listernick, B. R. Korf, P. L. Wolters and K. J. Johnson, Neurofibromatosis type 1, <em>Nat. Rev. Dis. Primer</em> <bold>3</bold> (2017) Article ID 17004; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/nrdp.2017.4" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/nrdp.2017.4</a>">https://doi.org/10.1038/nrdp.2017.4</ext-link>
    Search in Google ScholarBack to article
  2. A. S. Michaels, <em>Neurofibromatosis: Causes, Tests and Treatment Options</em> (2nd ed.), CreateSpace Independent Publishing Platform, Scotts Valley (CA, USA) 2014.
    Search in Google ScholarBack to article
  3. I. Solares, D. Viñal, M. Morales-Conejo, N. Rodriguez-Salas and J. Feliu, Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: A comprehensive review, ESMO Open <bold>6</bold>(4) (2021) Article ID 100223 (10 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.esmoop.2021.100223" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.esmoop.2021.100223</a>">https://doi.org/10.1016/j.esmoop.2021.100223</ext-link>
    Search in Google ScholarBack to article
  4. R. Roskoski, Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update, <em>Pharmacol. Res.</em> <bold>165</bold> (2021) Article ID 105463; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.phrs.2021.105463" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.phrs.2021.105463</a>">https://doi.org/10.1016/j.phrs.2021.105463</ext-link>
    Search in Google ScholarBack to article
  5. D. Casey, S. Demko, A. Sinha, P. S. Mishra-Kalyani, Y.-li Shen, S. Khasar, M. A. Goheer, W. S. Helms, L. Pan, Y. Xu, J. Fan, R. Leong, J. Liu, Y. Yang, K. Windsor, M. Ou, O. Stephens, B. Oh, G. H. Reaman, A. Nair, S. S. Shord, V. Bhatnagar, S. R. Daniels, S. Sickafuse, K. B. Goldberg, M. R. Theoret, R. Pazdur and H. Sing, FDA approval summary: Selumetinib for plexiform neurofibroma, <em>Clin. Cancer Res.</em> <bold>27</bold>(15) (2021) 4142–4146; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1158/1078-0432.CCR-20-5032" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1158/1078-0432.CCR-20-5032</a>">https://doi.org/10.1158/1078-0432.CCR-20-5032</ext-link>
    Search in Google ScholarBack to article
  6. U.S. Food &amp; Drug Administration, FDA Approves Selumetinib for Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas, US-FDA, Silver Spring (MD, USA), April 13, 2020; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas;">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selumetinib-neurofibromatosis-type-1-symptomatic-inoperable-plexiform-neurofibromas;</ext-link> last access date September 22, 2024.
    Search in Google ScholarBack to article
  7. S. V. Holt, A. Logié, R. Odedra, A. Heier, S. P. Heaton, D. Alferez, B. R. Davies, R. W. Wilkinson and P. D. Smith, The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models, <em>Br. J. Cancer</em> <bold>106</bold> (2012) 858–866; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1038/bjc.2012.8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1038/bjc.2012.8</a>">https://doi.org/10.1038/bjc.2012.8</ext-link>
    Search in Google ScholarBack to article
  8. C. Li, Z. Chen, H. Yang, F. Luo, L. Chen, H. Cai, Y. Li, G. You, D. Long, S. Li, Q. Zhang and L. Rao, Selumetinib, an oral anti-neoplastic drug, may attenuate cardiac hypertrophy via targeting the ERK pathway, <em>PloS One</em> <bold>11</bold> (2016) e-0159079; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1371/journal.pone.0159079" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1371/journal.pone.0159079</a>">https://doi.org/10.1371/journal.pone.0159079</ext-link>
    Search in Google ScholarBack to article
  9. FDA – Center for Drug Evaluation and Research, NDA Multi-disciplinary Review and Evaluation NDA 213756 Koselugo (selumetinib), Version July 24, 2019, US FDA-CDER, Silver Spring (MD, USA), February 2020; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf;">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf;</ext-link> last access date August 3, 2024.
    Search in Google ScholarBack to article
  10. K. K. Saindane, H. Talapadatur, V. K. Munipalli, R. M. Singh, B. Fegade and V. Bhaskar, Stability indicating RP-HPLC method for the estimation of selumetinib in capsule dosage form, <em>Int. J. Pharm. Sci. Rev. Res.</em> <bold>74</bold> (2022) 166–174; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.47583/ijpsrr.2022.v74i02.026" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.47583/ijpsrr.2022.v74i02.026</a>">https://doi.org/10.47583/ijpsrr.2022.v74i02.026</ext-link>
    Search in Google ScholarBack to article
  11. P. Severin, C. Bailey, M. Chen, A. Fisher and V. Holmes, Determination of selumetinib, <em>N</em>-desmethyl selumetinib and selumetinib amide in human biological samples by LC-MS/MS, <em>Bioanalysis</em> <bold>8</bold> (2016) 1919–1936; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.4155/bio-2016-0082" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.4155/bio-2016-0082</a>">https://doi.org/10.4155/bio-2016-0082</ext-link>
    Search in Google ScholarBack to article
  12. J. Li, Z. Zhang, M. Yan, S. Yang, Y. Song and J. Dong, Determination of selumetinib in rat plasma by UPLC-MS/MS and application to a pharmacokinetic study, <em>Lat. Am. J. Pharm.</em> <bold>39</bold> (2020) 237–342.
    Search in Google ScholarBack to article
  13. R. R. Voggu, T. S. Brus, C. T. Barksdale, P. Severin, P. Hansen, R. Chudnovskiy, E. Thomas and C. Bailey, Novel LC-MS/MS method for the determination of selumetinib (AZD6244) in whole blood collected with volumetric absorptive microsampling, <em>Bioanalysis</em> <bold>12</bold> (2020) 883–892; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.4155/bio-2020-0062" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.4155/bio-2020-0062</a>">https://doi.org/10.4155/bio-2020-0062</ext-link>
    Search in Google ScholarBack to article
  14. S. Alrubia, W. A. AlShehri, A. A. Radwan, N. Z. Alzoman and I. A. Darwish, Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro--5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation, <em>BMC Chemistry</em> <bold>19</bold> (2025) Article ID 27 (17 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1186/s13065-024-01353-6" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1186/s13065-024-01353-6</a>">https://doi.org/10.1186/s13065-024-01353-6</ext-link>
    Search in Google ScholarBack to article
  15. I. A. Darwish and N. Z. Alzoman, Development of green and high throughput microplate reader-assisted universal microwell spectrophotometric assay for direct determination of tyrosine kinase inhibitors in their pharmaceutical formulations irrespective the diversity of their chemical structures, <em>Molecules</em> <bold>28</bold>(10) (2023) Article ID 4049 (19 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/molecules28104049" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/molecules28104049</a>">https://doi.org/10.3390/molecules28104049</ext-link>
    Search in Google ScholarBack to article
  16. International Conference for Harmonisation (ICH), Harmonised Guideline Q2 (R1) Validation of Analytical Procedures: Text and Methodology, Geneva, Dec 2023; Retrieved from <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf;">https://database.ich.org/sites/default/files/ICH_Q2-R2_Document_Step2_Guideline_2022_0324.pdf;</ext-link> last access date March 18, 2025.
    Search in Google ScholarBack to article
  17. International Conference for Harmonisation (ICH)/EMA, Harmonised Guideline (M10) Bioanalytical Method Validation and Study Sample Analysis-Step 4, Geneva, May 2022; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf;">https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf;</ext-link> last access date March 18, 2025.
    Search in Google ScholarBack to article
  18. Waters, Wavelength cutoffs for common solvents; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://help.waters.com/help/en/product-support/alliance-is-system-support/715008450/6BCFA49.html;">https://help.waters.com/help/en/product-support/alliance-is-system-support/715008450/6BCFA49.html;</ext-link> last access date March 18, 2025.
    Search in Google ScholarBack to article
  19. A. Yusaf, M. Usman, A. Mansha, M. Siddiq, Z. Amjad, S. Irshad and H. Sultana, Self-organised surfactant assemblies as nanostructured dye carriers: a mixed micellar comparative approach for enhanced dye solubilisation, <em>Int. J. Environ. Anal. Chem.</em> <bold>104</bold> (2024) 2352–2363; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1080/03067319.2022.2060747" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1080/03067319.2022.2060747</a>">https://doi.org/10.1080/03067319.2022.2060747</ext-link>
    Search in Google ScholarBack to article
  20. A. A. Rana, A. Yusaf, S. Shahid, M. Usman, M. Ahmad, S. Aslam, S. A. Al-Hussain and M. E. A. Zaki, Unveiling the role of nonionic surfactants in enhancing cefotaxime drug solubility: A UV-visible spectroscopic investigation in single and mixed micellar formulations, <em>Pharmaceuticals</em> <bold>16</bold>(12) (2023) Article ID 1663; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.3390/ph16121663" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.3390/ph16121663</a>">https://doi.org/10.3390/ph16121663</ext-link>
    Search in Google ScholarBack to article
  21. P. Patel, E. Howgate, P. Martin, D. J. Carlile, L. Aarons and D. Zhou, Population pharmacokinetics of the MEK inhibitor selumetinib and its active <em>N</em>-desmethyl metabolite: data from 10 phase I trials, <em>Br. J. Clin. Pharmacol.</em> <bold>84</bold> (2018) 52–63; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1111/bcp.13404" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1111/bcp.13404</a>">https://doi.org/10.1111/bcp.13404</ext-link>
    Search in Google ScholarBack to article
  22. F. Shakeel, S. Alshehri, M. A. Ibrahim, M. Altamimi, N. Haq, E. M. Elzayat and G. A. Shazly, Solubilization and thermodynamic properties of simvastatin in various micellar solutions of different non-ionic surfactants: Computational modeling and solubilization capacity, <em>PLoS ONE</em> <bold>16</bold> (2021) e0249485; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1371/journal.pone.0249485" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1371/journal.pone.0249485</a>">https://doi.org/10.1371/journal.pone.0249485</ext-link>
    Search in Google ScholarBack to article
  23. ChemAxon. MarvinSketch Version 23.12., (Chemaxon Ltd., Budapest, Hungary); Retrieved from <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://chemaxon.com/marvin;">https://chemaxon.com/marvin;</ext-link> last access date March 18, 2025.
    Search in Google ScholarBack to article
  24. D. Malyshev, R. Öberg, L. Landström, P. O. Andersson, T. Dahlberg and M. Andersson, pH-induced changes in Raman, UV-Vis absorbance, and fluorescence spectra of dipicolinic acid (DPA), <em>Spectrochim. Acta A</em> <bold>271</bold> (2022) Article ID 120869 (8 pages); <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.saa.2022.120869" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.saa.2022.120869</a>">https://doi.org/10.1016/j.saa.2022.120869</ext-link>
    Search in Google ScholarBack to article
  25. S. Armenta, S. Garrigues and M. de la Guardia, Green analytical chemistry, <em>TrAC Trends Anal. Chem.</em> <bold>27</bold> (2008) 497–511; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.trac.2008.05.003" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.trac.2008.05.003</a>">https://doi.org/10.1016/j.trac.2008.05.003</ext-link>
    Search in Google ScholarBack to article
  26. A. Gałuszka, Z. M. Migaszewski, P. Konieczka and J. Namieśnik, Analytical Eco-Scale for assessing the greenness of analytical procedures, <em>TrAC Trends Anal. Chem.</em> <bold>37</bold> (2012) 61–72; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.trac.2012.03.013" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.trac.2012.03.013</a>">https://doi.org/10.1016/j.trac.2012.03.013</ext-link>
    Search in Google ScholarBack to article
  27. J. Płotka-Wasylka, A new tool for the evaluation of the analytical procedure: Green analytical procedure index, <em>Talanta</em> <bold>181</bold> (2018) 204–209; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1016/j.talanta.2018.01.013" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1016/j.talanta.2018.01.013</a>">https://doi.org/10.1016/j.talanta.2018.01.013</ext-link>
    Search in Google ScholarBack to article
  28. F. Pena-Pereira, W. Wojnowski and M. Tobiszewski, AGREE – Analytical GREEnness Metric approach and software, <em>Anal. Chem.</em> <bold>92</bold> (2020) 10076–10082; <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="<a href="https://doi.org/10.1021/acs.anal-chem.0c01887" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">https://doi.org/10.1021/acs.anal-chem.0c01887</a>">https://doi.org/10.1021/acs.anal-chem.0c01887</ext-link>
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/acph-2025-0013 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 407 - 426
Accepted on: Apr 12, 2025
Published on: Oct 10, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
selumetinib,
UV spectrophotometry,
HPLC-PDA,
green analytical chemistry,
pharmaceutical analysis
Related subjects:
Pharmacy,
Pharmacy, other

© 2025 Sarah Alrubia, Wafa A. Alshehri, Nourah Z. Alzoman, Ibrahim A. Darwish, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 75 (2025): Issue 3 (September 2025)Next article